Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

Stock Information for Nuwellis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nuwellis Inc.

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin
Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC?)
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.